Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TLR4 | O00206 | 7/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | CD69 | Q07108 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741377 | 1.00 | MAPK1 (0.50) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL2791012 | 0.96 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL10064893 | 0.96 | MAPK1 (0.54) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL17355650 | 0.93 | TLR4 (0.45) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16433507 | 0.90 | MAPK1 (0.53) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16800368 | 0.90 | MAPK1 (0.53) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL22098578 | 0.90 | MAPK1 (0.53) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL19225396 | 0.90 | MAPK1 (0.55) | MAPK1TLR4LGALS3LGALS8LGALS4 | |
| SCHEMBL16160411 | 0.90 | TLR4 (0.49) | MAPK1TLR4SELPLY96 | |
| SCHEMBL16160412 | 0.90 | TLR4 (0.49) | MAPK1TLR4SELPLY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090644-B2 | Processes for chemical synthesis of lipochitooligosaccharides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140303361-A1 | PROCESSES FOR CHEMICAL SYNTHESIS OF LIPOCHITOOLIGOSACCHARIDES | DU PONT (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120004401-A1 | COMPOSITIONS COMPRISING LIPOCHITOOLIGOSACCHARIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303361-A1 | PROCESSES FOR CHEMICAL SYNTHESIS OF LIPOCHITOOLIGOSACCHARIDES | PGLS, ALG1, DDOST | MAPK1 2558/4885TLR4 855/4885LGALS3 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.